Biotech Values

[rkrw]

I'm not sure or don't recall how much was known about the injection site issues prior to the actual pivotal trial data. You'd think had they known they wouldn't have wasted their time with a non-viable formulation.

Since Novo apparently does have their own ultra fast acting insulin, maybe that will spur one of their competitors to cover their bases and line up with Biodel.